Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy
Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies award for Young hematologists) at the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a bursary to attend the 2017 American Society of Hematology (ASH) Annual Meeting, taking place in the USA in December.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005748/en/
Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Young Hematologists in Rome, Italy (Photo: Business Wire)
Dr. Salamero is currently a hematologist at the Vall d’Hebron University Hospital, Barcelona, Spain and presented research entitled Very elderly acute promyelocytic leukemia: a multicentric experience. The study selected patients aged ≥ 75 years old with APL who had reported to PETHEMA registry (Spanish Hematology Treatment Programme) over the last nineteen years. Epidemiologic characteristics and disease features in the very elderly APL population were analysed and the percentage of patients treated according to investigators criteria described. The research found that patients treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimen showed better outcomes than patients who received other strategies, such as ATRA alone, chemotherapy alone or best supportive care.
Speaking after the awards ceremony, Dr. Salamero said, “Winning the tomy’s - it’s been a pleasure. I feel proud, not because of my work but the work of the PETHEMA group. I would recommend attending the APL Symposium as not only is it very interesting, but it facilitates a lot and keeps you in touch with your peers.”
The tomy’s are an educational award programme for young hematologists, sponsored by Teva Oncology. The awards are open to young hematologists, or young physicians training to become hematologists aged 40 years or younger. The entrants are challenged to illustrate the latest scientific advancements in the management of orphan hematological malignancies by presenting a case study or case series demonstrating their excellence in education and presentation skills. The independent jury for the 2017 tomy’s was comprised of experts in orphan hematological malignancies and includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco Lo-Coco, Italy; Bob Löwenberg, Netherlands; Nigel Russell, UK and Miguel Sanz, Spain.
“It’s estimated that between 1,500 – 2,000 people in Europe are diagnosed with APL each year. Even though APL is the most lethal type of acute leukemia, it’s highly curable and more research into this disorder is urgently needed. The tomy’s programme reflects Teva’s commitment to encouraging new and innovative research aimed at improving patient outcomes in orphan hematological malignancies,” said Paul Harmon, Head of Teva’s Oncology Care and Transplant Europe.
“APL can cause a number of symptoms including uncontrollable bleeding and can kill within hours or days if left untreated. As it’s so rare, APL can be difficult to recognise and diagnose. We’re excited about this programme, and we believe it will stimulate new exciting research, with the ultimate ambition of saving lives,” commented Prof. Lo-Coco, tomy jury member.
The full list of finalists as well as more information on the jury can be accessed via: https://www.thinkapl.com/jury/
The tomy’s awards ceremony in Rome follows the inaugural tomy’s awards, announced at the Teva Oncology Satellite Symposium at the Acute Leukemias XVI International Symposium, which took place in Munich, Germany, in February 2017.
For more information on the Tomy’s awards or for queries regarding abstract submissions or notifications, please contact: firstname.lastname@example.org.
Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
+31 6 2008 2545
+31 6 8201 5407
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group21.2.2018 14:02 | Pressemelding
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Puerto de Indias Group (“Puerto de Indias” or the “Company”), with the goal of accelerating the Company’s growth initiatives and supporting its expansion into international markets. Headquartered in Seville, Spain, Puerto de Indias was founded by Jose Antonio and Francisco Rodriguez Fernandez, and has become in a short period of time the leading player in the Rosé Gin market in Spain. Puerto de Indias has in place an ambitious international expansion plan targeting the development of a commercial network in Europe, the U.S., and Latin America, as well as strategic alliances with strong international distributors. Leopoldo Reaño, Principal at H.I.G. Europe, commented on the transaction: “We are thrilled to have the opportunity to support the management team led by Jose Antonio an
Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 13:02 | Pressemelding
Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As
Mavenir Unveils Its Industry First Mobile-Native UCaas Solution, Entering into a New UCC Market Category21.2.2018 13:00 | Pressemelding
Mavenir, a leader in mobile network transformation, today announced its industry first Mobile-Native Unified Communications and Collaboration as a Service (mUCaaS) solution, uniquely designed to address the specific mobility needs of SOHO and SMBs. Using mobile native wireless technologies while still supporting current communications desktop usage is a complete paradigm shift compared to traditional UCaaS offerings. Leveraging Mavenir’s expertise in mobile networks with Voice over LTE (VoLTE) and Rich Communication Services (RCS), the solution provides new recurring-revenue opportunities for mobile network operators (MNOs) while addressing the real business need for truly mobile communications for the workforce. MNOs are under pressure in the consumer market with flat growth, an intensive price war on voice and data plans, and fierce competition from OTT applications. The Enterprise market offers a better outlook with UCaaS telephony and messaging projecting growth of 15.2% CAGR1 2016
Medical Technology Leaders to Discuss Open Data During World Patient Safety, Science & Technology Summit21.2.2018 13:00 | Pressemelding
The medical technology field spans a multi-billion dollar market, and corporate competitiveness has long been viewed as the key to staying ahead. But Joe Kiani, Chairman, and CEO of the medical technology company, Masimo, is bringing fierce competitors together for the sake of patient safety. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005514/en/ Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation, discusses the importance of open data and interoperability of medical devices. (Photo: Business Wire) As a strong advocate for patient safety, Kiani founded the Patient Safety Movement Foundation to stem the needless deaths that occur in hospitals every day through preventable medical error. The goal is zero preventable deaths by 2020. One of the ways to reach such an aggressive goal, says Kiani, is a concept called “interoperability” and he wants to use open data to create a “Patient Data Super Highw
Mavenir and ADVA Ensemble Partner to Deliver Enterprise LTE Solutions to Managed Service Providers and Enterprises21.2.2018 12:00 | Pressemelding
Mavenir, focused on transforming mobile network economics for Communications Service Providers, and Ensemble, a Division of ADVA Optical Networking, the leader in Edge NFV solutions, have partnered to provide a complete end-to-end solution for Enterprise LTE. The Enterprise LTE Solution empowers mobile network operators with a revenue-generating solution offering for businesses looking to replace outdated and expensive hardware-based wireless networks. Enterprise solutions require low cost white box architectures that are zero touch from an install perspective. To add complete LTE wireless connectivity to that solution allows the enterprise to install their own partial or complete LTE enterprise wireless that is capable of supporting CBRS and multicarrier solutions. The total global revenue for the private LTE addressable market in industrial and commercial IoT will reach $118.5 billion in 20231. Leveraging NFV as a platform for new and innovative applications, Ensemble and Mavenir hav
The Russian Export Center Will Be Presenting Innovative Russian Solutions at the Mobile World Congress in Barcelona for the First Time21.2.2018 11:21 | Pressemelding
The Russian Export Center will be introducing home-grown, Russian technology at the 2018 Mobile World Congress (MWC) in Barcelona for the first time. Seventeen Russian companies will showcase their unique, powerful and competitive solutions to a world audience from February 26th to March 1st, from the Russian Booth (Pavilion No. 6, booth 6H20 and 6I11). Information about Russian companies attending is available via the link below: https://drive.google.com/file/d/1pNZ5d8ZOSrC5Ltf_ro_oQVZoo2ylnWqY/view A special business program is organized for the Russian booth, to create opportunities for Russian companies to enter the international market and non-Russian companies to promote their business in Russia. We would like to welcome media and attendees to special events at the Russian Export Center exposition including: - A special session with the leading Russian newspaper "Kommersant", titled "New business opportunities in the digital age" involving Russian and foreign experts (February 26